Darren Snellgrove Elevated to Lead Investor Relations at Johnson & Johnson as Jessica Moore Moves to Innovative Medicine Finance Leadership

Johnson & Johnson has unveiled significant leadership changes in its finance and investor relations functions, effective May 1, 2025, underscoring the company’s robust internal talent pipeline. The moves position two seasoned executives in expanded roles that reflect their proven track records within the healthcare conglomerate.

Jessica Moore, who has successfully stewarded the Investor Relations division since 2021, will transition to serve as Group Chief Financial Officer for Johnson & Johnson’s Innovative Medicine segment. This promotion recognizes her strong operational oversight and financial acumen demonstrated throughout her tenure managing relationships with analysts and investors. According to Joseph Wolk, Executive Vice President and Chief Financial Officer, Moore’s combination of leadership capability and substantive finance expertise uniquely qualifies her to drive financial strategy for the Innovative Medicine business unit.

Snellgrove’s Appointment Signals Confidence in Internal Bench

Darren Snellgrove has been selected as the new Vice President of Investor Relations, taking on the responsibility of communicating Johnson & Johnson’s strategic direction, governance framework, and value drivers to the investment community. Wolk emphasized that Snellgrove’s extensive experience across multiple business divisions—including Innovative Medicine, MedTech, Research & Development, and Business Development—provides the necessary foundation for the role.

Snellgrove brings a quarter-century of financial leadership to the position. Most recently, he served as Group Chief Financial Officer for Innovative Medicine, where he oversaw the financial performance and analytical functions of the segment. Under his tenure in this capacity, the Innovative Medicine business achieved above-market growth trajectories while maintaining strategic investment in innovation pipelines. Prior roles included Vice President of Finance for Innovative Medicine R&D and Vice President of Finance for Johnson & Johnson Innovation and Pharmaceutical Business Development.

Background and Credentials

Snellgrove joined Johnson & Johnson in 1999, building his career through increasingly senior positions across the organization’s core business units. He holds a bachelor’s honors degree in economics and philosophy from Southampton University in the United Kingdom and earned his MBA from Villanova University.

Both executives will continue to report directly to Joseph Wolk, ensuring continuity in financial oversight and investor engagement functions. The appointments reflect Johnson & Johnson’s commitment to developing leadership pathways and promoting career advancement from within its organizational structure.

About Johnson & Johnson

Johnson & Johnson operates at the intersection of healthcare innovation, leveraging expertise in Innovative Medicine and MedTech to address complex health challenges globally. The company focuses on preventing, treating, and curing disease through intelligent therapeutic approaches and personalized solutions, positioning itself across the spectrum of modern healthcare delivery.